This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include WuXi XDC’s acquisition of TOT Biopharm to expand ADC CDMO capabilities, Sino Biopharma’s entry into RNAi therapeutics with the acquisition of Hygieia, and RemeGen’s US$ 5.6 billion licensing deal with AbbVie. IPO filings by Exegenesis, Immvira, and Genhouse Bio, along with licensing deals from Zonsen, MediLink, and SciNeuro, underscore progress in gene therapy, ADCs, and radioligand therapeutics. Clinical breakthroughs, including approvals for Hengrui’s bifunctional fusion protein and Sunshine Lake’s SGLT2 inhibitor, reflect significant advancements in addressing unmet medical needs.
